RT Journal Article
SR Electronic
T1 Bucillamine use for rheumatoid arthritis and type 2 diabetes mellitus are associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.02.22282616
DO 10.1101/2022.12.02.22282616
A1 Tsuji, Takahiro
A1 Iwasaki, Sari
A1 Makita, Keishi
A1 Furukawa, Shota
A1 Watanabe-Kusunoki, Kanako
A1 Takeda-Otera, Sayo
A1 Itoh, Takahito
A1 Shimamoto, Mamiko
A1 Yamaji, Hiroaki
A1 Yoshimura, Tomomasa
A1 Yamamoto, Junya
A1 Kudo, Takashi
A1 Kondo, Makoto
A1 Kataoka, Hiroshi
A1 Mukai, Masaya
A1 Kaga, Yukito
A1 Yoshinari, Miku
A1 Nishibata, Yuka
A1 Masuda, Sakiko
A1 Tomaru, Utano
A1 Ishizu, Akihiro
A1 Fukasawa, Yuichiro
A1 Hashimoto, Seiji
A1 Nishio, Saori
YR 2022
UL http://medrxiv.org/content/early/2022/12/05/2022.12.02.22282616.abstract
AB Membranous nephropathy (MN) is a disease characterized by deposition of immune complexes on the glomerular basement membrane. More than 10 specific antigens for MN including M-type phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A), exostosin 1/exostosin 2 (EXT1/EXT2) and neural epidermal growth factor-like 1 (NELL1) have so far been identified. Since the clinicopathologic characteristics of each type of MN in Japanese are not well understood, we first examined 107 cases of MN by immunohistochemistry for four antigens (PLA2R, THSD7A, EXT1, and NELL1) (MN-cohort). Of those 107 cases, 40% were PLA2R-positive, 13% were NELL1-positive, 11% were THSD7A-positive, 5% were EXT1-positive, 2% were PLA2R and NELL1-double-positive, and 29% were quadruple-negative. In one case of PLA2R and NELL1-double-positive, the first biopsy showed PLA2R-positive and the second biopsy showed PLA2R and NELL1-double-positive. Of the 16 cases of NELL1-positive, 12.5% had colon cancer, 18.8% had rheumatic diseases treated with bucillamine, and 63% had type 2 diabetes mellitus (T2DM). Next, 34 patients diagnosed with MN who had rheumatoid arthritis (RA) were examined (RA-MN cohort). Of those 34 patients, 79% were NELL1-positive, 6% were PLA2R-positive, and 15% were quadruple-negative. In the RA-MN cohort, 56% had a history of bucillamine use. In conclusion, NELL1-associated MN is a common MN in patients with RA using bucillamine and may also be associated with T2DM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of Sapporo City General Hospital gave ethical approval for this work (Approval No. R02-060-759)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors